New FDA requirements could provide opportunities for Genmab, CEO says

Genmab CEO Jan van de Winkel thinks the FDA’s new project, Optimus, could be good for the firm, as it will require more work do be done to find the optimal dosage of cancer treatments.

Photo: PR / Genmab

New guidelines from the US Food and Drug Administration (FDA) concerning the development of cancer treatments could have a big impact on the sector, says Genmab’s CEO Jan van de Winkel.

At the end of January, the FDA launched a new project, Optimus, which will require companies developing cancer drugs to do more work to find the optimal dose, so that the best effect can be achieved with the lowest possible dosage.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs